Welcome to our dedicated page for Larimar Therapeutics news (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics stock.
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with its lead compound, nomlabofusp, in development as a potential treatment for Friedreich’s ataxia (FA). The Larimar news feed on Stock Titan aggregates the company’s press releases and related coverage so readers can follow key milestones in this rare disease program.
News about Larimar frequently centers on clinical data updates from the ongoing long-term open-label and open-label extension studies of nomlabofusp in FA. The company has reported increases in skin frataxin (FXN) levels with daily subcutaneous dosing, directional improvements in clinical outcome measures such as mFARS, FARS-ADL, 9-Hole Peg Test, and Modified Fatigue Impact Scale, and long-term safety observations including injection site reactions and anaphylaxis events. Larimar also publishes nonclinical findings that describe the mechanism of action and pharmacology of nomlabofusp as an FXN protein replacement therapy.
Another major category of LRMR news involves regulatory interactions and timelines. Larimar has disclosed written recommendations from the U.S. Food and Drug Administration on the safety database needed for its Biologics License Application and the agency’s openness to using skin FXN concentrations as a reasonably likely surrogate endpoint for an accelerated approval pathway. The company regularly issues press releases on these regulatory updates, its participation in the START pilot program, and its targeted timing for a BLA submission seeking accelerated approval.
Investors and followers will also see financial results and capital markets announcements, including quarterly operating and financial updates, underwritten public offerings of common stock, and the use of proceeds to fund nomlabofusp development and other pipeline plans. For a consolidated view of LRMR-related developments—spanning clinical, regulatory, and financing events—this news page provides an organized stream of Larimar’s own disclosures and market-facing communications.
Larimar Therapeutics (Nasdaq: LRMR) announced that CEO Carole Ben-Maimon will participate in the William Blair Biotech Focus Conference 2021, scheduled virtually for July 14-15. Dr. Ben-Maimon will engage in a fireside chat on July 15 at 3:00 PM ET, discussing the company's development of treatments for complex rare diseases. Larimar's lead candidate, CTI-1601, is being evaluated for Friedreich's ataxia in a Phase 1 program. A replay of the chat will be accessible on Larimar's website.
Larimar Therapeutics (Nasdaq: LRMR) announced that CEO Carole Ben-Maimon will present at the JMP Securities Life Sciences Conference on June 16-17, 2021. The presentation will take the form of a fireside chat scheduled for 2:00 PM ET on June 16. Larimar focuses on developing treatments for rare diseases, currently evaluating its lead compound, CTI-1601, in a Phase 1 clinical program for Friedreich’s ataxia. The company aims to utilize its platform for creating fusion proteins targeting additional rare diseases.
Larimar Therapeutics (Nasdaq: LRMR) announced a clinical hold by the FDA on its CTI-1601 program due to mortalities observed in a non-human primate toxicology study. The company will not proceed with its planned private placement financing. CEO Carole Ben-Maimon emphasized patient safety and confirmed ongoing evaluation of data to comply with FDA requirements, potentially delaying upcoming trials into 2022. Larimar has $81.4 million in cash, sufficient for operations through mid-2022, and continues to believe in a viable path for CTI-1601’s development.
Larimar Therapeutics (Nasdaq: LRMR) announced a private placement financing raising approximately $95 million. The transaction involves the issuance of around 7,096,048 shares at a price of $13.43 per share. The funds will support the clinical development of CTI-1601, a treatment for Friedreich's ataxia, and other corporate purposes. Notable investors include Deerfield Management and RA Capital Management. The placement is expected to close by May 25, 2021.
Larimar Therapeutics (Nasdaq: LRMR) announced that the European Medicines Agency granted Priority Medicines (PRIME) designation for CTI-1601, a recombinant fusion protein aimed at treating Friedreich’s ataxia (FA). This designation comes after positive data from nonclinical and Phase 1 clinical studies, indicating that CTI-1601 can deliver human frataxin effectively. Larimar also holds multiple designations from the FDA, facilitating its development process. The company plans to initiate further clinical trials in the latter half of the year, enhancing its position in addressing rare diseases.
Larimar Therapeutics announced promising results from its Phase 1 clinical trial of CTI-1601, aimed at treating Friedreich's ataxia. The study demonstrated that daily subcutaneous injections over 13 days significantly increased frataxin levels in various tissues compared to placebo, achieving levels similar to healthy carriers. Safety data indicated that CTI-1601 was well tolerated without serious adverse events. The company plans future trials, including a pediatric study. This breakthrough could address critical unmet needs in FA treatment.
Larimar Therapeutics (Nasdaq: LRMR) reported its Q1 2021 results, highlighting significant progress in its Phase 1 trial for Friedreich's ataxia (FA). The company has cash and investments amounting to $81.4 million as of March 31, 2021, with a net loss of $12.1 million or $0.76 per share. The increase in R&D expenses to $9.0 million reflects higher clinical costs and personnel hiring. Management announced that topline data from the Phase 1 study will be revealed on May 11, 2021, which will include crucial pharmacodynamic data.
Learmar Therapeutics, Inc. (Nasdaq: LRMR) reported its preliminary Phase 1 findings for CTI-1601, a treatment for Friedreich's ataxia, indicating safety and tolerability in doses up to 100 mg. The company holds $92.6 million in cash as of December 31, 2020, despite a net loss of $42.5 million for the year, reflecting increased R&D costs due to clinical trials and personnel. Topline data from ongoing placebo-controlled trials is anticipated in Q2 2021, alongside the initiation of new trials aimed at further advancing CTI-1601's development.
BALA CYNWYD, Pa., Feb. 18, 2021 – Larimar Therapeutics (Nasdaq: LRMR) announced that Dr. Carole Ben-Maimon, CEO, will present at the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021. The presentation is scheduled for February 26, 2021, at 8:00 AM ET, in a fireside chat format. Larimar is a clinical-stage biotech firm focused on therapies for rare diseases, notably evaluating CTI-1601 for Friedreich’s ataxia. More information can be found via their website.
Larimar Therapeutics has been added to the NASDAQ Biotechnology Index effective December 21, 2020. This index tracks biotechnology and pharmaceutical companies on the NASDAQ exchange. Larimar, focusing on treatments for complex rare diseases, is developing its lead compound, CTI-1601, for Friedreich’s ataxia. The index’s recognition may enhance visibility and potentially attract more investors to Larimar, reflecting its active involvement in the biotechnology sector.